-CODE 980.10



HET WEIGHT

PYRENONE® DISINSECTION 5-1 M.A.G. CONCENTRATE

INSECTICIDE

EPA Reg. No. 4816-436

ACTIVE INGREDIENTS	
Pyrethrins	1.0%
*Piperonyl Butoxide, Technical	
"INERT INGREDIENTS	
	100.0%

- *Equivalent to 4.0% of (butylcarbityl) (6-propylpiperonyl) ether and 1.0% of related compounds.
- **Contains Petroleum Oil

CAUTION: KEEP OUT OF REACH OF CHILDREN

Harmful if swallowed.


This product is toxic to fish. Do not contaminate lakes or streams by cleaning equipment or disposal of wastes.

Do not reuse empty drum. Return to drum reconditioner or destroy by perforating or crushing and burying in a safe place.

PYRENONE - Registered Trademark FMC Corporation

FOR MANUFACTURING USE ONLY

TERMS OF SALE OR USE: On purchase or use of this product buver and user agree to the following conditions: WARRANTY: Niagara warrants that this product, as of the time of sale by Niagara, (1) conforms to the ingredient statement on the label, and (2) is reasonably fit for the purposes set forth in the Directions for Use. EXCEPT AS SO WARRANTED THE PRODUCT IS SOLD AS IS. NIAGARA WAKES NO OTHER WARRANTY EXPRESS OF IMPLIED. DAMAGES: Buver's or user's exclusive remedy for damages for breach of warranty or negligence shall be immitted to direct damages more exceeding the purchase price paid and shall not include incidental or consequential damages. Notice of any claim must be reported to Niagara within 10 days of discovery by buyer or user, failing which buyer or user waives any claim for such damage. EXCUSE FROM NON-CONTROLLABLE CONDITIONS: Because of certain critical conditions created or incurred by Suver or user or over which Niagara has no control, buyer and user, as a condition of purchase or use, assume responsibility for and release Niagara from, liability arising out of the handling or use of the product attributable to such causes. No person is authorized to vary or waive any statement contained nerein.



Not Reviewed. Registrant claims to be in accordance with the secondance of Pesticide Product Cuidance for Phase 2 (2008), Page 2002, Active to Inert Change in Status.